This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (172) CIHR funded proposals with peer-review reports (Canada) (43)

Published on in Vol 6, No 8 (2017): August

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Authors of this article:

Ian Gilron1 Author Orcid Image ;   Dongsheng Tu2 Author Orcid Image ;   Ronald Holden2 Author Orcid Image ;   Tanveer Towheed2 Author Orcid Image ;   Elizabeth Vandenkerkhof2 Author Orcid Image ;   Roumen Milev2 Author Orcid Image
Article Authors Cited by (2) Tweetations (3) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.